VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression

被引:188
作者
George, ML
Tutton, MG
Janssen, F
Arnaout, A
Abulafi, AM
Eccles, SA
Swift, RI
机构
[1] Inst Canc Res, Sect Canc Therapeut, Sutton SM2 5NG, Surrey, England
[2] Mayday Univ Hosp, Colorectal Unit, Croydon CR7 7YE, Surrey, England
[3] Mayday Univ Hosp, Dept Histopathol, Croydon CR7 7YE, Surrey, England
来源
NEOPLASIA | 2001年 / 3卷 / 05期
关键词
angiogenesis; immunohistochemistry; staging; lymphatic; adenoma-carcinoma;
D O I
10.1038/sj.neo.7900186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We aimed to assess the relationship of the angiogenic cytokines VEGF-A, VEGF-C, and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in the adenoma-carcinoma sequence and in metastatic spread of colorectal cancer (CRC). mRNA expression levels were measured using semi-quantitative reverse transcription polymerase chain reaction in 70 CRC (35 with paired mucosae) and 20 adenomatous polyps. Immuohistochemistry and ELISA assessed protein expression. VEGF-D mRNA expression was significantly lower in both polyps and CRCs compared with normal mucosa (P=.0002 and .002, respectively), whereas VEGF-A and VEGF-C were significantly raised in CRCs (P=.006 and .004, respectively), but not polyps (P=.22 and P=.5, respectively). Receptor expression was similar in tumor tissue and normal mucosae. Tumors with lymph node metastases had significantly higher levels of VEGF-A compared with non-metastatic tumors (P=.043). There was no association between VEGF-C or VEGF-D and lymphatic spread. The decrease in VEGF-D occurring in polyps and carcinomas may allow the higher levels of VEGF-A and VEGF-C to bind more readily to the VEGF receptors, and produce the angiogenic switch required for tumor growth. Increased expression of VEGF-A within CRCs was associated with lymphatic metastases, and therefore, this member of the VEGF family may be the most important in determining metastatic spread.
引用
收藏
页码:420 / 427
页数:8
相关论文
共 48 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues [J].
Akagi, K ;
Ikeda, Y ;
Miyazaki, M ;
Abe, T ;
Kinoshita, J ;
Maehara, Y ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :887-891
[3]  
André T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO
[4]  
2-5
[5]  
BROWN LF, 1993, CANCER RES, V53, P4727
[6]   Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features [J].
Bunone, G ;
Vigneri, P ;
Mariani, L ;
Butó, S ;
Collini, P ;
Pilotti, S ;
Pierotti, MA ;
Bongarzone, I .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1967-1976
[7]   Vascular endothelial growth factor C induces angiogenesis in vivo [J].
Cao, YH ;
Linden, P ;
Farnebo, J ;
Cao, RH ;
Eriksson, A ;
Kumar, V ;
Qi, JH ;
Claesson-Welsh, L ;
Alitalo, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14389-14394
[8]  
Cascinu S, 2000, CLIN CANCER RES, V6, P2803
[9]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[10]  
Eggert A, 2000, CLIN CANCER RES, V6, P1900